Prognostic Factors Influencing the Selection of Bevacizumab Combined With Chemotherapy in Patients With HER2-Negative Metastatic Breast Cancer in Routine Clinical Practice. Oncosur-Avalox: Observational Cross-Sectional Study
| Autor: | Rosa Llorente, Cristina Llorca, Cristina Grávalos, J. Casinello, Luis Manso, Gustavo Catalan, A. García Palomo, J.I. Chacon Lopez-Muniz, E. Galve Calvo, Ramon Perez-Carrion |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Chemotherapy Bevacizumab Cross-sectional study business.industry medicine.medical_treatment Hematology medicine.disease Gastroenterology Metastatic breast cancer chemistry.chemical_compound Regimen Oncology Paclitaxel chemistry Docetaxel Internal medicine medicine Hormonal therapy business medicine.drug |
| Zdroj: | Annals of Oncology. 23:ix125 |
| ISSN: | 0923-7534 |
| DOI: | 10.1016/s0923-7534(20)32906-9 |
| Popis: | Background Combining bevacizumab (BEV) with chemotherapy (CT) improves survival in HER2-negative metastatic breast cancer (MBC). We investigated the influence of age, ECOG, hormonal status, number of sites and location of metastases and patient decision on the selection of BEV combined with CT in MBC. Methods Observational cross-sectional multicenter study in pts with HER2- negative MBC who have received first-line CT with BEV. Results From November 2010 to November 2011, 124 pts were included: median age 51 (45-64) yr; ECOG: 0 = 50%; 60% pre-menopausic; 23% triple-negative (TN); 77% hormone receptorpositive (HR+). Metastatic disease: ≥3 sites = 42% (TN: 32%; HR + : 45%); location: 44% bone, 35% lung, 30% liver. Most frequent BEV-based combinations were paclitaxel/BEV (53%) and docetaxel/BEV (14.5%); median no. of CT cycles: 6 (5-8). A disease-free survival (DFS) ≥12 months was achieved by 73%; TN: 68%; HR + : 76%. Overall response rate (ORR) was 58%: 51% partial response (PR), 7% complete response (CR); 28% stable disease (SD) and 10% disease progression. TN: ORR 44% (40% PR), clinical benefit 80% (36% SD); HR + : ORR 62% (54% PR), clinical benefit 87% (25% SD). 58% presented at least one toxicity, mainly grade 1-2; 26% BEV-related: only 3 (2.4%) grade 3 toxicities; no grade 4. Receiving adjuvant hormonal therapy was associated to DFS ≥12 months (p Conclusions Our findings suggest that first-line CT with BEV is an active and tolerable treatment option for pts with TN and HR+ MBC. ER+ tumors and a single metastatic site were identified as independent factors for the selection of a paclitaxel-BEV therapy. The presence of metastases in the liver was significantly associated to the administration of a paclitaxel-BEV regimen. Disclosure All authors have declared no conflicts of interest. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|